Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amorfix gains rights to brain disease target
The protein superoxide dismutase-1 (SOD1) is known to misfold and aggregate in the neurological disease amyotrophic lateral sclerosis (ALS). In addition to the licensing rights, the company also
The protein superoxide dismutase-1 (SOD1) is known to misfold and aggregate in the neurological disease amyotrophic lateral sclerosis (ALS). In addition to the licensing rights, the company also
Innovate has been partnering Avantogen on the development of the promising pancreatic chemo-resistance inhibitor, RP101. In executing the merger, Innovate will acquire the Australian company’s interest in the
The trial is designed to determine the safety and tolerability of EUR-1008M and will compare the active drug to placebo in improving absorption of fat and other nutrients.
The two companies will collaborate to identify clinical candidates from a certain class of Dr Reddy’s’ compounds for use as potential treatments for chronic obstructive pulmonary disease (COPD).
Fast track designation is given to drugs that promise to fulfill unmet medical needs for serious diseases. The designation should allow for an accelerated review process, potentially bringing
The new formulation uses a bi-layer tablet delivery system, which controls the release of the pseudoephedrine component for consistent delivery. The recommended twice-daily dosing of the drug will
The therapy being developed utilizes Altea Therapeutics’ PassPort transdermal technology to deliver an active pharmaceutical ingredient to the patient. Under the terms of the agreement, Teikoku Seiyaku will
Hycamtin, already approved as a treatment for ovarian cancer, is the first drug to be approved in Europe that is specifically indicated for the treatment of relapsed small
Avandaryl combines Avandia and Amaryl, two other diabetes drugs for the control of blood sugar levels. As an adjunct to diet and exercise, Avandaryl is indicated to improve
The phase II trial will be conducted at US transplant centers in donors and patients undergoing stem cell transplants. Success in this patient population would support Vical’s expansion